Trevena’s Chronic Pain Therapy Granted U.S. Patent

Trevena’s Chronic Pain Therapy Granted U.S. Patent
Trevena, Inc. has been granted a U.S. patent for TRV734, its investigational treatment for acute and chronic moderate-to-severe pain, as well as compositions comprising TRV734, and methods of using TRV734. The U.S. Patent and Trademark Office (USPTO) awarded U.S. Patent No. 9,044,469, and the company expects to hold full patent coverage for TRV734 until at least 2032. Trevena is focused on researching and developing biased ligands able to target the G protein coupled receptors (GPCRs), and TRV734 is expected to treat patients with severe and chronic pain. The USPTO granted the company a patent entitled "Opioid Receptor Ligands and Methods of Using and Making Same," as the company is currently studying TRV734 in a phase 1 clinical trial. “This patent provides long-term protection in the United States for the TRV734 molecule and its use in treating pain,” stated the CEO of Trevena, Maxine Gowen, PhD. “With this issued U.S. patent, and corresponding patent applications pending in key international markets, we are well positioned to establish a comprehensive and global intellectual property estate for this important asset. TRV734 is expected to improve analgesia and reduce on-target gastrointestinal and central nervous system adverse effects with an innovative mode of action at the mu-opioid receptor. The investigational oral treatment is similar to the company's intravenous treatment for the same indication, as it is a biased ligand at the mu-opioid receptor, activating the G protein pathway, related to analgesia, but preventing the activation of the mu-opioid beta-arrestin pathw
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *